Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is positioned for significant growth, particularly with Dupixent, which is projected to reach ~$21 billion in US peak sales by 2030, driven by expansion into new indications and strong physician overlap. The collaboration with Sanofi is expected to enhance profitability, with an anticipated increase in collaboration revenue of $1 billion by 2027, following the repayment of development costs by 3Q26, thereby improving overall margins. Additionally, the company's diversified growth strategy, supported by strong performances in Eylea and Libtayo, along with new allergy programs from successful Phase III trials, reinforces a positive outlook for Regeneron’s revenue streams over the next year.

Regeneron Pharmaceuticals is currently experiencing a negative outlook primarily due to declining sales of EYLEA, which are impacted by the introduction of biosimilars and a sluggish transition to EYLEA HD. The company's pipeline is under pressure from intense competition and uncertainty regarding the success of development programs, which could hinder future revenue growth and management’s ability to execute strategic plans. Additionally, there are concerns that Dupixent may not meet revenue expectations both domestically and internationally, and that Libtayo might fail to satisfy investor expectations in the Non-Small Cell Lung Cancer market, potentially resulting in weaker-than-expected revenues and earnings per share.